Showing all 3 results
The Oncomine Acute Myeloid Leukaemia (AML) Panel is a targeted next-generation sequencing (NGS) assay designed for comprehensive genomic profiling of AML. It enables simultaneous detection of key mutations, gene fusions, and copy number variations across clinically relevant genes associated with AML.
The Oncomine Comprehensive Myeloid/Leukemia Panel (DNA + RNA fusions) is a next-generation sequencing (NGS) assay designed for comprehensive genomic profiling of myeloid malignancies and leukemias. It simultaneously analyzes DNA and RNA to detect key mutations, copy number variations, and gene fusions across a broad range of clinically relevant genes.
The Oncomine Myeloproliferative Neoplasm (MPN) Panel is a targeted next-generation sequencing (NGS) assay designed for the comprehensive detection of key driver mutations in myeloproliferative neoplasms. It enables the simultaneous analysis of JAK2, CALR, and MPL genes, which are critical for MPN diagnosis and classification. The panel offers high sensitivity, detecting low-frequency variants with as little as 10 ng of input RNA or DNA, making it ideal for limited or degraded samples.